JO3719B1 - 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139 - Google Patents

4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139

Info

Publication number
JO3719B1
JO3719B1 JOP/2015/0282A JOP20150282A JO3719B1 JO 3719 B1 JO3719 B1 JO 3719B1 JO P20150282 A JOP20150282 A JO P20150282A JO 3719 B1 JO3719 B1 JO 3719B1
Authority
JO
Jordan
Prior art keywords
gpr139
benzotriazines
dihydro
oxo
controls
Prior art date
Application number
JOP/2015/0282A
Other languages
English (en)
Inventor
Holly Reichard
Betty Lam
Holger Monenschein
Stephen Hitchcock
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of JO3719B1 publication Critical patent/JO3719B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

يتعلق الاختراع الحالي بطريقة لمعالجة مرض، اضطراب أو حالة يصاحبها GPR139 باستخدام مركبات من الصيغة 1: 1 التي هي معضدات لأجل GPR139، بمركبات معينة تدخل في الصيغة 1، بتركيبات دوائية منها، بعمليات لصنع المركبات، وبمركبات وسطية منها.
JOP/2015/0282A 2014-11-20 2015-11-18 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139 JO3719B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462082539P 2014-11-20 2014-11-20
US201562184729P 2015-06-25 2015-06-25

Publications (1)

Publication Number Publication Date
JO3719B1 true JO3719B1 (ar) 2021-01-31

Family

ID=55022667

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0282A JO3719B1 (ar) 2014-11-20 2015-11-18 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139

Country Status (40)

Country Link
US (5) US9556130B2 (ar)
EP (2) EP3536324B1 (ar)
JP (2) JP6637501B2 (ar)
KR (1) KR102582021B1 (ar)
CN (2) CN107108531B (ar)
AU (1) AU2015349866B2 (ar)
CA (1) CA2968242C (ar)
CL (1) CL2017001292A1 (ar)
CO (1) CO2017005959A2 (ar)
CR (1) CR20170275A (ar)
CY (2) CY1122613T1 (ar)
DK (2) DK3536324T3 (ar)
DO (1) DOP2017000120A (ar)
EA (1) EA033728B1 (ar)
EC (1) ECSP17038999A (ar)
ES (2) ES2734735T3 (ar)
GE (1) GEP20196961B (ar)
HR (2) HRP20212009T1 (ar)
HU (2) HUE044145T2 (ar)
IL (1) IL252311B (ar)
JO (1) JO3719B1 (ar)
LT (2) LT3536324T (ar)
MA (1) MA40993B1 (ar)
MD (1) MD3221298T2 (ar)
MX (1) MX378158B (ar)
MY (1) MY187423A (ar)
NZ (1) NZ732208A (ar)
PE (1) PE20170899A1 (ar)
PH (1) PH12017500920B1 (ar)
PL (2) PL3221298T3 (ar)
PT (2) PT3221298T (ar)
RS (2) RS59078B1 (ar)
SG (1) SG11201704002UA (ar)
SI (2) SI3536324T1 (ar)
SM (2) SMT202200142T1 (ar)
TN (1) TN2017000196A1 (ar)
TW (1) TWI684590B (ar)
UA (1) UA120375C2 (ar)
UY (1) UY36406A (ar)
WO (1) WO2016081736A1 (ar)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3719B1 (ar) 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
US12042496B2 (en) 2018-10-16 2024-07-23 The University Of Florida Research Foundation, Incorporated Methods related to opioid therapeutics
WO2020097609A1 (en) * 2018-11-09 2020-05-14 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
PH12022550597A1 (en) * 2019-09-16 2024-03-04 Takeda Pharmaceuticals Co Azole-fused pyridazin-3(2h)-one derivatives
WO2021127459A1 (en) * 2019-12-20 2021-06-24 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
WO2021224680A1 (en) * 2020-05-08 2021-11-11 Takeda Pharmaceutical Company Limited Substituted benzotriazinone metabolites of a gpr139 agonist
TW202227087A (zh) * 2020-09-21 2022-07-16 日商武田藥品工業股份有限公司 精神分裂症之治療
US11760788B2 (en) 2021-03-02 2023-09-19 Pathways Neuro Pharma, Inc. Neuroreceptor compositions and methods of use
WO2023165262A1 (zh) * 2022-03-01 2023-09-07 上海科技大学 噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用
WO2023165263A1 (zh) * 2022-03-01 2023-09-07 上海科技大学 吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用
CN117986183A (zh) * 2022-10-28 2024-05-07 浙江友宁生物医药科技有限公司 一种gpr139受体激动剂、其制备方法及其应用
WO2024102802A1 (en) * 2022-11-11 2024-05-16 Takeda Pharmaceutical Company Limited Zelatriazin for the treatment of depression
WO2025119351A1 (zh) * 2023-12-08 2025-06-12 深圳湾实验室 Gpr139激动剂
CN120424068A (zh) * 2024-02-02 2025-08-05 上海科技大学 稠杂环类化合物与其制备方法、药物组合物及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794726A (en) * 1972-08-21 1974-02-26 Uniroyal Inc Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one
WO1987004928A1 (fr) 1986-02-24 1987-08-27 Mitsui Petrochemical Industries, Ltd. Agents therapeutiques de la neuropathie
DE3850742T2 (de) * 1987-11-04 1994-10-27 Beecham Group Plc Neue 4-Oxobenzotriazine und 4-Oxochinazoline.
CA2526506A1 (en) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
CA2533824A1 (en) 2003-07-31 2005-02-10 Irm, Llc Bicyclic compounds and compositions as pdf inhibitors
FR2875805B1 (fr) 2004-09-27 2006-12-29 Genfit S A Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
JP2010521513A (ja) * 2007-03-23 2010-06-24 エフ．ホフマン−ラ ロシュ アーゲー アザ−ピリドピリミジノン誘導体
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011138265A2 (en) 2010-05-03 2011-11-10 Evotec Ag Indole and indazole derivatives as orexin receptor antagonists
JP2016515138A (ja) * 2013-03-14 2016-05-26 ヤンセン ファーマシューティカ エヌ．ベー． Ｇｐｒ１３９の生理的リガンド
JO3719B1 (ar) * 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139

Also Published As

Publication number Publication date
JP6637501B2 (ja) 2020-01-29
US20160145218A1 (en) 2016-05-26
HUE057451T2 (hu) 2022-05-28
PH12017500920A1 (en) 2017-11-20
US20170095480A1 (en) 2017-04-06
DOP2017000120A (es) 2017-06-15
GEP20196961B (en) 2019-03-25
LT3536324T (lt) 2021-12-10
PH12017500920B1 (en) 2017-11-20
MY187423A (en) 2021-09-22
US11173161B2 (en) 2021-11-16
CY1124929T1 (el) 2023-01-05
AU2015349866B2 (en) 2020-12-03
KR20170084324A (ko) 2017-07-19
CY1122613T1 (el) 2021-05-05
CN112062730A (zh) 2020-12-11
MA40993A (fr) 2017-09-27
US20190070187A1 (en) 2019-03-07
MD3221298T2 (ro) 2019-10-31
AU2015349866A1 (en) 2017-06-15
IL252311A0 (en) 2017-07-31
EP3221298B1 (en) 2019-04-03
KR102582021B1 (ko) 2023-09-22
EP3536324B1 (en) 2021-10-06
CL2017001292A1 (es) 2018-02-16
SG11201704002UA (en) 2017-06-29
BR112017010311A2 (pt) 2017-12-26
CO2017005959A2 (es) 2017-10-20
US9556130B2 (en) 2017-01-31
CN112062730B (zh) 2023-09-29
NZ732208A (en) 2023-02-24
PT3221298T (pt) 2019-06-28
HRP20212009T1 (hr) 2022-04-01
ES2897545T3 (es) 2022-03-01
RS62563B1 (sr) 2021-12-31
EA201791096A1 (ru) 2017-11-30
IL252311B (en) 2020-07-30
ECSP17038999A (es) 2017-10-31
SI3536324T1 (sl) 2021-12-31
MX378158B (es) 2025-03-10
SMT201900355T1 (it) 2019-07-11
WO2016081736A1 (en) 2016-05-26
ES2734735T3 (es) 2019-12-11
US20170348319A1 (en) 2017-12-07
UY36406A (es) 2016-06-30
DK3536324T3 (da) 2021-10-25
PT3536324T (pt) 2021-11-10
DK3221298T3 (da) 2019-06-24
SI3221298T1 (sl) 2019-10-30
CN107108531B (zh) 2020-10-20
CR20170275A (es) 2017-10-30
JP2020063285A (ja) 2020-04-23
PL3221298T3 (pl) 2019-10-31
CA2968242A1 (en) 2016-05-26
LT3221298T (lt) 2019-08-12
TW201625566A (zh) 2016-07-16
US9770450B2 (en) 2017-09-26
CN107108531A (zh) 2017-08-29
SMT202200142T1 (it) 2022-05-12
MA40993B1 (fr) 2019-07-31
PE20170899A1 (es) 2017-07-12
US10561662B2 (en) 2020-02-18
UA120375C2 (uk) 2019-11-25
TN2017000196A1 (en) 2018-10-19
HRP20191003T1 (hr) 2019-08-23
EP3536324A1 (en) 2019-09-11
MX2017006448A (es) 2017-09-12
JP6918088B2 (ja) 2021-08-11
JP2017535559A (ja) 2017-11-30
TWI684590B (zh) 2020-02-11
US10159677B2 (en) 2018-12-25
RS59078B1 (sr) 2019-09-30
EP3221298A1 (en) 2017-09-27
EA033728B1 (ru) 2019-11-20
CA2968242C (en) 2022-11-08
HUE044145T2 (hu) 2019-09-30
PL3536324T3 (pl) 2022-02-07
US20200129518A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
JO3719B1 (ar) 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
JO3466B1 (ar) مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
MX388170B (es) Polimorfos de selinexor
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
MX2018000880A (es) Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r).
EA201891376A1 (ru) Бензотиофеновые селективные блокаторы эстрогеновых рецепторов
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
JOP20170100B1 (ar) توليف مركبات إندازول
PL3142785T3 (pl) Sposób wytwarzania alkenoli i ich zastosowanie do wytwarzania 1,3- butadienu
BR112017010177A2 (pt) composição para tratamento de tecido
EA201790982A1 (ru) Синтез копанлисиба и его дигидрохлорида
PH12016501613A1 (en) Pyrazines modulators of gpr6
IN2015CH01182A (ar)
BR112016027455A2 (pt) moduladores ppar
EA201792282A1 (ru) Способы лечения заболеваний
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
EA201691465A1 (ru) Средство для лечения сердечно-сосудистых заболеваний
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs
TH149082A (th) องค์ประกอบชนิดใหม่, การเตรียมของสารเหล่านี้ และการใช้ของสารเหล่านี้สำหรับผลิตโพลีเอไมด์ที่เป็นตัวหล่อ
TR201401730A2 (tr) Artroz'un semptomatik tedavisine yönelik bir kompozisyon.